Essential Thrombocythemia Market

Essential Thrombocythemia (ET), an uncommon blood cancer, is one of the classic myeloproliferative neoplasms. It is a condition in which the bone marrow produces too many platelets. Patients with ET have increased numbers of platelets. Red blood cell numbers are generally normal in ET, while white blood cell numbers are normal or slightly elevated in ET.

The estimates show the highest prevalence of ET in the United States with 142,635 cases.

The total prevalent population of Essential Thrombocythemia in the 7MM was 232,688 in 2017.

Among the European five countries, France had the highest prevalent population of Essential Thrombocythemia with 20,141 cases, followed by Germany and the United Kingdom.

A higher percentage of symptomatic prevalence was observed in the US, in comparison to other 7MM countries during the study period (2017–2030).

For more information on Essential Thrombocythemia Market, visit:
https://www.delveinsight.com/report-store/essential-thrombocythemia-ET-market-insights